Pfizer Settles Foreign Bribery Charges, Wins Deferred Prosecution For Helping Government
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer reaches separate settlements with DoJ and SEC to resolve charges its subsidiaries bribed foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ.
You may also be interested in...
Foreign Bribery Investigations Ramping Up, Along With 'Carrot' For Cooperation
Pilot program from DOJ reduces fines for companies that voluntarily disclose misconduct; focus of investigations is broadening from sales to suppliers.
Translating The Foreign Corrupt Practices Act Into Practice: DoJ/SEC Offer Pragmatic Enforcement Guide
The FCPA resource guide gives examples of cases the DoJ and SEC have decided not to prosecute and describes the hallmarks of an effective compliance program; PhRMA, GPhA among groups that were asking for more clarity.
Pfizer On Track To Settle Rapamune Investigation; Protonix Probe Still Unresolved
Pfizer has reached an agreement-in-principle with the Department of Justice in the Rapamune investigation and taken a charge of $491 million; Novartis settles allegations over the marketing of Elidel for $19.9 million.